The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Genomic factors underlying resistance to immunotherapy in newly diagnosed multiple myeloma
Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses the results of a study which used whole genome sequencing (WGS) on bone marrow (BM) malignant plasma cells to assess the genetic determinants of resistance to immunotherapy in patients with newly diagnosed multiple myeloma (NDMM) treated with daratumumab, carfilzomib, lenalidomide and dexamethasone (DaraKRd). Dr Maura highlights that many mutations were associated with resistance, requiring further investigation to improve response to immunotherapy in these patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
